Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

THE TRUTH ABOUT: Antares pharma | History Defined

Looking Into Antares Pharma's Return On Invested Capital

Benzinga Pro data, Antares Pharma (NASDAQ:ATRS) reported Q1 sales of $41.56 million. Earnings fell to a loss of $2.32 million, resulting in a 107.1% decrease from last quarter.

Benzinga · Jun 8, 2022

LPCN: First Quarter 2022 Financial and Operational Results

By John Vandermosten, CFA NASDAQ:LPCN READ THE FULL LPCN RESEARCH REPORT

Benzinga · May 10, 2022

Benzinga's Top Ratings Upgrades, Downgrades For April 14, 2022

Upgrades

Benzinga · Apr 14, 2022

From analysis to the latest developments in health,
read the most diverse news in one place.

Halozyme Buys Antares In $960M Deal To Create One Drug Delivery, Specialty Product Entity

Halozyme Therapeutics Inc (NASDAQ:HALO) will acquire Antares Pharma Inc (NASDAQ:ATRS) for $5.60 per share, valuing Antares at approximately $960 million. The transaction is expected to be accretive to Halozyme's 2022 revenue and adjusted earnings and accelerate top-and bottom-line growth through 2027, with multiple growth drivers beyond 2027. Antares' suite of FDA-approved and partner products utilizing…

Benzinga · Apr 13, 2022

Antares Pharma's Oral Testosterone Treatment Scores FDA Approval

Antares Pharma Inc (NASDAQ:ATRS) has nabbed another FDA approval, and the Company's second involving testosterone. The Company announced FDA approval for Tlando (testosterone undecanoate), an oral treatment for testosterone replacement therapy indicated for deficiency or absence of endogenous testosterone or hypogonadism. The first time the Company got a testosterone product approved by…

Benzinga · Mar 29, 2022

LPCN: 2021 Results

By John Vandermosten, CFA NASDAQ:LPCN READ THE FULL LPCN RESEARCH REPORT

Benzinga · Mar 11, 2022

Antares Pharma's Return On Capital Employed Overview

According to Benzinga Pro, during Q4, Antares Pharma (NASDAQ:ATRS) earned $32.68 million, a 506.03% increase from the preceding quarter. Antares Pharma also posted a total of $48.73 million in sales, a 1.12% increase since Q3.

Benzinga · Mar 8, 2022

Read news from The Economist, FT, and more,
with one subscription

Antares Pharma: Q4 Earnings Insights

Antares Pharma (NASDAQ:ATRS) reported its Q4 earnings results on Thursday, March 3, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Benzinga · Mar 3, 2022

Earnings Outlook For Antares Pharma

Antares Pharma (NASDAQ:ATRS) is set to give its latest quarterly earnings report on Thursday, 2022-03-03. Here's what investors need to know before the announcement. Analysts estimate that Antares Pharma will report an earnings per share (EPS) of $0.01.

Benzinga · Mar 2, 2022

Coverage From

Benzinga

People

John Vandermosten

46 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

SolarEdge Technologies

33 stories

Marqeta

25 stories

Read news from The Economist, FT, and more,
with one subscription

Places

United States

424,095 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.